Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management (Q38110527)

29 August 2017

title

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management (English)

1 reference

29 August 2017

main subject

systemic mastocytosis

1 reference

Animesh Pardanani

1

1 reference

29 August 2017

publication date

30 May 2013

1 reference

American Journal of Hematology

29 August 2017

published in

1 reference

29 August 2017

volume

88

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

612-624

1 reference

Bone marrow findings in systemic mastocytosis

29 August 2017

cites work

1 reference

Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease

21 January 2018

1 reference

Pediatric-onset mastocytosis: a long term clinical follow-up and correlation with bone marrow histopathology

21 January 2018

1 reference

Urticaria pigmentosa: a review of 67 pediatric cases

21 January 2018

1 reference

Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

21 January 2018

1 reference

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.

21 January 2018

1 reference

Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge

21 January 2018

1 reference

Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia.

21 January 2018

1 reference

Significance of systemic mast cell disease with associated hematologic disorders

21 January 2018

1 reference

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

21 January 2018

1 reference

Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis

21 January 2018

1 reference

KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation

21 January 2018

1 reference

Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior

21 January 2018

1 reference

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

21 January 2018

1 reference

One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes

21 January 2018

1 reference

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

21 January 2018

1 reference

Mast cell disease associated with acute myeloid leukemia: detection of a new c-kit mutation Asp816His

21 January 2018

1 reference

Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.

21 January 2018

1 reference

c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation

21 January 2018

1 reference

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

21 January 2018

1 reference

Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis

21 January 2018

1 reference

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy

21 January 2018

1 reference

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

21 January 2018

1 reference

A germline mutation in KIT in familial diffuse cutaneous mastocytosis

21 January 2018

1 reference

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation

21 January 2018

1 reference

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit.

21 January 2018

1 reference

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

21 January 2018

1 reference

Expression of a constitutively active mutant of M-Ras in normal bone marrow is sufficient for induction of a malignant mastocytosis/mast cell leukemia, distinct from the histiocytosis/monocytic leukemia induced by expression of activated H-Ras.

21 January 2018

1 reference

How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage).

21 January 2018

1 reference

Histopathological and immunohistochemical aspects of mastocytosis.

21 January 2018

1 reference

CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.

21 January 2018

1 reference

Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).

21 January 2018

1 reference

Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis

21 January 2018

1 reference

Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease

21 January 2018

1 reference

Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients

21 January 2018

1 reference

Mast cells as "tunable" effector and immunoregulatory cells: recent advances.

21 January 2018

1 reference

Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology

21 January 2018

1 reference

Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

21 January 2018

1 reference

Evaluation of the WHO criteria for the classification of patients with mastocytosis.

21 January 2018

1 reference

Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.

21 January 2018

1 reference

Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal

21 January 2018

1 reference

Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients.

21 January 2018

1 reference

Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype study

21 January 2018

1 reference

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.

21 January 2018

1 reference

Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

21 January 2018

1 reference

International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.

21 January 2018

1 reference

Response of severe systemic mastocytosis to interferon alpha

21 January 2018

1 reference

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

21 January 2018

1 reference

Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine

21 January 2018

1 reference

Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature

21 January 2018

1 reference

In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.

21 January 2018

1 reference

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

21 January 2018

1 reference

Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia

21 January 2018

1 reference

Treatment of systemic mast-cell disease with cladribine

21 January 2018

1 reference

Cladribine therapy for systemic mastocytosis.

21 January 2018

1 reference

Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

21 January 2018

1 reference

Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms

21 January 2018

1 reference

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

21 January 2018

1 reference

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

21 January 2018

1 reference

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial

21 January 2018

1 reference

Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis

21 January 2018

1 reference

Advanced mast cell disease: an Italian Hematological Multicenter experience

21 January 2018

1 reference

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

21 January 2018

1 reference

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

21 January 2018

1 reference

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

21 January 2018

1 reference

Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.

21 January 2018

1 reference

Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

21 January 2018

1 reference

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

21 January 2018

1 reference

Dasatinib therapy for systemic mastocytosis: four cases

21 January 2018

1 reference

Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

21 January 2018

1 reference

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study

21 January 2018

1 reference

Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy

21 January 2018

1 reference

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23459

1 reference

29 August 2017

1 reference